Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) Sees Significant Drop in Short Interest

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 17,100 shares, a drop of 54.6% from the August 30th total of 37,700 shares. Based on an average daily volume of 41,700 shares, the short-interest ratio is presently 0.4 days. Currently, 0.2% of the shares of the stock are sold short.

NVIV traded up $0.02 during midday trading on Friday, hitting $0.50. 6,191 shares of the company traded hands, compared to its average volume of 15,944. The company has a current ratio of 5.72, a quick ratio of 5.72 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $4.56 million, a price-to-earnings ratio of -0.22 and a beta of 1.54. Invivo Therapeutics has a 52-week low of $0.45 and a 52-week high of $2.75. The business has a 50 day simple moving average of $0.57 and a two-hundred day simple moving average of $0.90.

Invivo Therapeutics (NASDAQ:NVIV) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Invivo Therapeutics will post -1.25 earnings per share for the current year.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.

Read More: Google Finance

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.